NCT04409483View on ClinicalTrials.gov

Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Covid-19
Interventions
DRUG

Lopinavir-Ritonavir Drug Combination

400mg/100mg taken orally twice daily for 14 days.

COMBINATION_PRODUCT

Standard Care

Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily

Sponsors

Lead Sponsor

Epicentre
All Listed Sponsors
collaborator

Université Abdou Moumouni

UNKNOWN

collaborator

Centre de Recherche Médicale et Sanitaire

OTHER

collaborator

Ministry of Public Health, Republic of Niger

UNKNOWN

lead

Epicentre

OTHER

NCT04409483 - Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger | Biotech Hunter | Biotech Hunter